Borlaug, M.D., Javed Butler, M.D., Sren Rasmussen, Ph.D., Melanie Davies, M.D., G
These predispositions may help provide context about your baseline metabolic traits and how your body's peptide signaling systems respond to dual-agonist therapy
Insurance coverage can be a major deciding factorif one is covered while the other isnt, cost may ultimately determine your choice
This precise formulation maximizes therapeutic efficacy while maintaining a high safety profile for long-term use
However, specific clinical scenarios warrant baseline and follow-up testosterone assessment to ensure appropriate hormonal balance during treatment and to identify any underlying endocrine disorders that may require intervention